TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Endomyometritis incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Characteristic strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weibull modulus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction of overall discomfort
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: reduction of nasal secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: better functional results at rhinomanometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: 3-month healing rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median 2 year survival
Endpoint domain: Mortality/survival
Primary endpoint: Time to in-field progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intracyclic bleeding episodes
Endpoint domain: Adverse events/effects
Primary endpoint: neurologic sequelae
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: hearing loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Loss of Lean Mass (LM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Loss of Visceral Adipose Tissue (VAT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pre-discharge exclusive breastfeeding rates
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Healing rate of ESD-induced ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Rates of granulation lesions following ulcer healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Medication cost of treatment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Elevated factor VIII activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Acute damage to the tubal epithelium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: complete polyp regression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: nausea experience
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Greene scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Psychological parameters of anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Blood hormone profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: CKMB levels in coronary sinus blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: rSO2 measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Risk of development of PRCa
Endpoint domain: Mortality/survival
Primary endpoint: time spent in moderate hyperglycemia after lunch
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: hyperglycemic time after breakfast
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 24‐h urinary isoprostanes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mammography screening in the last year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lymphocyte GPx4 protein concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: GPx4 activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Baseline concentrations of IL-8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Baseline concentrations of ET-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in VEGF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RTOG score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: acute side‐effects of radiation
Endpoint domain: Adverse events/effects
Primary endpoint: flare rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heparin responsiveness during CPB
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Invasive infection
Endpoint domain: Adverse events/effects
Primary endpoint: Lower oesophageal sphincter pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: therapeutic efficacy of Philips TL 01/100W
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Resting gastrocnemius muscle stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Ascitic lactate dehydrogenase (LDH) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PMNL counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cefotaxime treatment effectiveness
Endpoint domain: Adverse events/effects
Primary endpoint: Appropriate ICD therapy received
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Decrease in plasma homocysteine concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cumulative percentage of death or myocardial infarction
Endpoint domain: Mortality/survival
Primary endpoint: Transient ischemia
Endpoint domain: Adverse events/effects
Primary endpoint: Beta‐blocker therapy discontinuation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Perceived appropriateness of withholding treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pain at rest and during movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total oxycodone consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: percent change of mean-IMT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: heart frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: diastolic pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Side effects due to conversion
Endpoint domain: Adverse events/effects
Primary endpoint: Moderate or complete response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: discharge utilization of ACE inhibitors or ARBs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Joint inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lameness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decreased GFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Progression towards tobacco use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of cardiovascular disease (CVD) events
Endpoint domain: Mortality/survival
Primary endpoint: Increase in daytime symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reactive hyperemia index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: C‐reactive protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Functional nocturnal continence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cure of esophagitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: GIQLI change
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Prednisone dose requirements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Steroid-sparing effect
Endpoint domain: Adverse events/effects
Primary endpoint: 30-day quit rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: staff distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: BDNF level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: average pain during 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RDQ scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Visual acuity of 20/200 or better
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retinal reattachment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity for detecting advanced colorectal neoplasms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: serum BNP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: DeltaP(max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Delivery rates per transfer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Multiple delivery rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bony consolidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in delusion score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean number of hereditary angioedema attacks per month
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean fasting blood glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: plasma concentrations of nutrients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of mobilization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of hematuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Pre-frailty
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pathologic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Energy delivery time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimum number of RF applications needed to achieve block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: compliance of GPs with guidelines
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Mean plaque-size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Deterioration of penile curvature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rates
Endpoint domain: Adverse events/effects
Primary endpoint: Training usefulness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Upper body endurance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average M value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Frequency of insulin dose modification
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Frequency of hypoglycaemia
Endpoint domain: Adverse events/effects
Primary endpoint: Adalimumab trough level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: graft dislodgement
Endpoint domain: Adverse events/effects
Primary endpoint: total area of formed biofilm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Canadian Cardiovascular Society angina score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximal myocardial oxygen consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: sCD40l levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: chromosome damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of deletions per cell
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of dicentrics per cell
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: recurrent ischemic stroke or death
Endpoint domain: Mortality/survival
Primary endpoint: Recession
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Differential methylation at DMR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: duration of fluoroscopy
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: endovascular material costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Plasma lysergic acid diethylamide concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Half-life of lysergic acid diethylamide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute subjective and sympathomimetic responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Future severe exacerbations
Endpoint domain: Adverse events/effects
Primary endpoint: Future poor asthma control
Endpoint domain: Adverse events/effects
Primary endpoint: Increased risk of future extreme salbutamol overuse
Endpoint domain: Adverse events/effects
Primary endpoint: Postoperative radicular and back pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for opioids in the early postsurgery period
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in rotation and flexion-extension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SF-36 physical function and energy and vitality scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Non-smoking rate after 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mRS 0-1 and mRS 0-2 rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Hematoma volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Average Barthel scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pain relief 6h after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knee joint range of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adenoma detection rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Adenoma miss rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Prediction accuracy of colorectal lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Ventricular end-diastolic pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of women using a reliable method of contraception
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incident diabetes development
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: maximal knee-extension force
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients achieving prespecified INR target
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of clerks using PDA
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of encounters recorded
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of evaluations recorded
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Mean lumbar spine BMD change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean femoral neck BMD change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Foot Function Index (FFI)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Weekly seizure frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Prevalence of symptomatic PDA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: perceived ethical problems significance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: ability to discern specific ethical problems
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Ventilation difference during saline infusions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: H+ concentration during exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: morbidity and mortality
Endpoint domain: Adverse events/effects
Primary endpoint: Quality of recovery scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: ACPA reactivity levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in albuminuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: BV loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean care cost
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: treatment complications
Endpoint domain: Adverse events/effects
Primary endpoint: mini-mental status examination (MMSE) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: change in ADL (ADCS-ADL) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CSF Aβ42 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Postoperative mortality rate
Endpoint domain: Mortality/survival
Primary endpoint: MASI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Risk perception improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: definite bacteremia/sepsis/meningitis
Endpoint domain: Adverse events/effects
Primary endpoint: positive blood culture result
Endpoint domain: Adverse events/effects
Primary endpoint: Improved children's safety knowledge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Simulated risk behaviors with water
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in PHN-related pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VTE incidence
Endpoint domain: Mortality/survival
Primary endpoint: Time for platelet recovery to 20 x 10(9)/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Time for platelet recovery to 50 x 10(9)/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Average number of megakaryocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: 24-h mean GH concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Pulsatile GH secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: long-term reductions in drinking behaviour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lacrimal drainage function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: post procedural pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity in identifying malignant tumors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Specificity in identifying malignant tumors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: serious bacterial infection-related events
Endpoint domain: Adverse events/effects
Primary endpoint: Total symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Recall of important articles
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Knowledge of articles' conclusions
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Median interval from randomization to delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Incidence of postdates pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Incisional SSI incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Organ/space SSI incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Child Health and Illness Profile‐Child Edition: Parent Report Form (CHIP‐CE:PRF) Achievement and Risk Avoidance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Weiss Functional Impairment Rating Scale‐Parent (WFIRS‐P) total score
Endpoint domain: Life impact
Endpoint subdomain: Functional outcomes
Primary endpoint: Change in HAM-D17 scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes